The coverage gap in Medicare Part D is not taking as big a bite out of coverage this year as originally expected. But pharma is still nervous about what will happen to patients who do fall in the donut hole. And, though the numbers affected this year may not be as large as feared, pharma comapnies need to learn as much as they can about the impact of the donut hole under Part D.
By Michael McCaughan
September 22 was supposed to be a big day for critics of Medicare Part D. Dubbed "Donut Hole Day" by...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Patient access to mental health drugs also will be challenged by the policies in the new budget reconciliation legislation.
States also agreed to fund patient travel to specialized treatment centers as part of their participation in the Medicaid demo of CMS-negotiated outcomes-based contracts for Vertex/CRISPR's Casgevy and bluebird bio's Lyfgenia.
The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.
PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.
